References
- 1. Coppo R, Cattran D. The new oxford clinic-pathological classification of IgA nephropathy. Sec Biol Med Sci. 2010;1:241-8.
- 2. Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis. 2010;17:469-79.10.1053/j.ackd.2010.09.002
- 3. Presta P, Minutolo R. Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10-year follow-up. Eur J Intern Med. 2011;22:90-4.10.1016/j.ejim.2011.08.021
- 4. Wright JT, Bakris G, Greene Т. African American study of kidney disease and hypertension study group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2013;288:2421-31.10.1001/jama.288.19.2421
- 5. López-Novoa J, Rodríguez-Peña A, Ortiz A, Martínez-Salgado C, López Hernández F. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. Nephrology (Saint-Petersburg). 2013;17(2):9-38.
- 6. Okon K, Sulowicz W, Smolenski O. Interstitial, tubular and vascular factors in progression of rimary glomerulonephritis. Pol J Pathol. 2017;58(2):73-8.
- 7. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;43(22):113-27.
- 8. Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury – where do we stand today? Nephrol Dial Transplant. 2011;26(3):762-4.10.1093/ndt/gfr006
- 9. Ding H, He Y, Li K, Yang J, Li X, Lu, et al. Urinary neutrophil gelatinase-associated lipocalin is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol. 2017; 42:227-34.
- 10. Bolignano D, Coppolino G, Campo S. Urinary neutrophil gelatinase-associated lipocalin is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant. 2008;23:414-6.10.1093/ndt/gfm541
- 11. Bolignano D, Lacquaniti A, Coppolino G. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):44-237.10.2215/CJN.03530708
- 12. Huang F, Horikoshi S, Kurusu A. Urinary levels of interleukin-18 and disease activity in patients with IgA nephropathy. J Clin Lab Anal. 2011;15(1):30-4.10.1002/1098-2825(2001)15:1<30::AID-JCLA6>3.0.CO;2-X
- 13. Beili S, Ni Z, Cao L, Zhou M. Serum IL-18 Is closely associated with renal tubulointerstitial injury and predicts renal prognosis in IgA Nephropathy. Mediators Inflamm. 2012;2:1-9.
- 14. Shimizu C, Fuijta T, Fuke Y, Ito K, Satomura A, Matsomuto K, Soma M. High circulating levels of the Interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus. Mod Rheumatol. 2012;22(1):73-9.10.3109/s10165-011-0471-2